Nivolumab a New Standard of Care in Adjuvant Settings in Esophageal and Gastroesophageal Junctional Cancer Patients

Senthil J. Rajappa1 Syed Nusrath2

1Department of Medical Oncology, Basavatarakam Indo American Cancer Institute and Research Institute, Hyderabad, Telangana, India
2Department of Surgical Oncology, Division of Upper Gastrointestinal Surgery, Basavatarakam Indo American Cancer Institute and Research Institute, Hyderabad, Telangana, India

Ind J Med Paediatr Oncol 2021;42:468–469.

There exists a significant risk of recurrence after neoadjuvant chemoradiotherapy (NCRT) and surgery among the three-fourths of patients with carcinoma esophagus who do not achieve complete pathological remission (PCR). Therefore, CheckMate 577 (CM577), a global, randomized, double-blind, placebo-controlled phase 3 trial, has explored the role of an immune checkpoint inhibitor (ICPI), Nivolumab as adjuvant therapy in patients with esophageal or gastro-esophageal junction (GEJ) cancer who did not achieve a PCR.

In clinical trials of previously treated patients with advanced esophageal or GEJ tumors with squamous-cell carcinoma (SCC) or adenocarcinoma histology, the overall survival (OS) in the nivolumab arm was higher than those who received either chemotherapy or placebo. These results led to the conduct of the CM577 study.

The authors need to be commended for carrying out such a unique study of its kind. Among patients with completely resected stage II or III esophageal or GEJ cancer (R0 resection) who had received NCRT and did not achieve a PCR, an impressive doubling of disease-free survival (DFS) was seen in the nivolumab arm in comparison with the placebo arm. However, the literature to support DFS as a valid surrogate to OS in esophageal cancer is not robust.

In the multicentric randomized NEOCRETEC 5010 trial evaluating the role of NCRT in stage II and III esophageal SCC, where the standards of surgery were high, the median DFS in surgery alone arm was 41.7 months at 34.6 months of follow-up. In CM577, at 2 years median follow-up, the median DFS was 29 months on the adjuvant Nivolumab arm for patients with SCC and R0 resection. This DFS on the CM577, despite preoperative chemoradiation, R0 resection, and adjuvant nivolumab, is grossly inferior to the DFS on the surgery alone arm of the NEOCRETEC 5010 study. One of the potential reasons for the inferior outcome in the CM577 could be the poor quality of surgery.

In the CROSS trial, the benefits of NCRT in terms of OS were better for squamous histology than adenocarcinoma. Hence, in the CM577 trial, we would expect the DFS on the placebo arms to be higher for squamous histology than adenocarcinoma. However, for unexplained reasons, the DFS on the placebo arms was strikingly similar for both histologies at 11 months.
The CM577 study used a tumor proportion score (TPS) rather than a combined positive score (CPS) to quantify PDL1 expression. Adjutant nivolumab in subset analysis did not show benefit on PDL1 expression by CPS. However, post hoc analysis by CPS showed that patients with higher CPS (>5) benefitted from adjuvant nivolumab (29.4 vs. 10.2 months). In those with CPS <5 (n = 295), the difference was smaller (16.3 vs. 11.1 months), hazard ratio (HR) was 0.89, and confidence interval (CI) was 0.65–1.22.

In recently published ICPI studies in advanced esophageal/GEJ and gastric cancers, the PDL1 expression only by CPS correlated with outcomes. In the Checkmate 649 and Keynote 590 trials, patients whose tumors had higher CPS benefitted better with the addition of ICPI to chemotherapy.10,11 In the subset analysis of the Keynote 590 study, the OS benefit was driven by the subset of patients with higher CPS (>10).11 Similarly, in Checkmate 649, the clinical significance of OS benefit of 2 months with an HR of 0.8 (0.68–0.94, p = 0.0002) in the intention to treat (ITT) population is questionable.10 We understand that PDL1 is not a robust biomarker. The magnitude of nivolumab benefit may be better in patients with a higher PDL1 expression by CPS based on CM577 and other ICPI studies in advanced settings. We feel that it would be appropriate to stratify patients in CM577 based on CPS rather than TPS.

In the subset analysis, DFS was better when patients were randomized >10 weeks after surgery compared with those randomized earlier. Earlier institution of adjuvant systemic therapy is associated with better outcomes than delayed therapy. A common reason for the delayed start of adjuvant therapy is delayed recovery from surgery, which could reflect the need for more extensive surgery, and is associated with higher disease stages, poor biology, and inferior outcomes. This finding in CM577 is contrary to our expectations and is worth further analysis.

The absolute magnitude of DFS benefit of adjuvant nivolumab was better for SCC (29.7 vs. 11 months) than adenocarcinoma (19 vs. 11 months). Similarly, whether the lack of benefit in GEJ tumors could be due to a higher proportion of adenocarcinoma in this population, is worth a thought. This differential effect of adjuvant nivolumab based on the histology and anatomical subsite needs further evaluation. In the forest plot, patients with ypT3T4 seemed to have a better outcome in the standard arm compared with lower stages, which is not expected. This is possible only if the lower T stages had more patients with nodal positivity. However, this information is missing in the study.

Although our observations are based on subset analysis and hypotheses generation, these findings are quite glaring and clinically relevant to be ignored. We feel that the benefits of adjuvant nivolumab in terms of DFS are likely to be restricted to patients with esophageal SCC. In the absence of a demonstrable OS benefit so far, clinicians need to be judicious while recommending adjuvant nivolumab to all subsets of patients as approved by the Foods and Drugs Administration (FDA).

**Declaration**

The authors disclose no financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work.

**Funding**

None.

**Conflict of Interest**

None declared.

**References**